Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells

  • Sánchez-Cid, Lourdes
  • Pons, Mònica
  • Lozano, Juan José
  • Rubio, Nuria
  • Guerra-Rebollo, Marta
  • Soriano, Aroa|||0000-0001-9659-1471
  • Paris-Coderch, Laia
  • Segura, Miquel F.
  • Fueyo Arévalo, Raquel
  • Arguimbau, Judit
  • Zodda, Erika
  • Bermudo, Raquel
  • Alonso, Immaculada
  • Caparrós, Xavier
  • Cascante, Marta
  • Rafii, Arash
  • Kang, Yibin
  • Martínez-Balbás, Marian
  • Weiss, Stephen J.
  • Blanco Fernández, Jerónimo
  • Muñoz, Montserrat
  • Fernández, Pedro Luis|||0000-0002-8618-4597
  • Thomson, Timothy M.
MicroRNAs are critical regulators of gene networks in normal and abnormal biological processes. Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression in tumor samples of several microRNAs, including the miR-200 family, along progression from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b and miR-7 in IDC patients with regional or distant metastases relative to patients with primary node-negative tumors. Forced expression of miR-200s in MCF10CA1h mammary cells induced an enhanced epithelial program, aldehyde dehydrogenase (ALDH) activity, mammosphere growth and ability to form branched tubuloalveolar structures while promoting orthotopic tumor growth and lung colonization in vivo. MiR-200s also induced the constitutive activation of the PI3K-Akt signaling through downregulation of PTEN, and the enhanced mammosphere growth and ALDH activity induced in MCF10CA1h cells by miR-200s required the activation of this signaling pathway. Interestingly, the morphology of tumors formed in vivo by cells expressing miR-200s was reminiscent of metaplastic breast cancer (MBC). Indeed, the epithelial components of MBC samples expressed significantly higher levels of miR-200s than their mesenchymal components and displayed a marker profile compatible with luminal progenitor cells. We propose that microRNAs of the miR-200 family promote traits of highly proliferative breast luminal progenitor cells, thereby exacerbating the growth and metastatic properties of transformed mammary epithelial cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma

  • Soriano, Aroa|||0000-0001-9659-1471
  • Masanas, Marc|||0000-0002-2249-8554
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Masiá, Núria
  • París-Coderch, Laia|||0000-0003-2145-5752
  • Piskareva, Olga
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Henrich, Kai-Oliver
  • Roma, Josep|||0000-0001-7692-6123
  • Westermann, Frank
  • Stallings, Raymond L.
  • Sábado, Constantino|||0000-0003-3956-5466
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
The online version of this article (10.1007/s00018-019-03041-4) contains supplementary material, which is available to authorized users., Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the genome, remains largely unexplored. RNA therapeutics is an emerging field that widens the range of druggable targets and includes elements such as microRNA. Here, we sought to screen for microRNA with tumor-suppressive functions in neuro-blastoma, an aggressive pediatric tumor of the sympathetic nervous system that requires the development of new therapies. We found miR-323a-5p and miR-342-5p to be capable of reducing cell proliferation in multiple neuroblastoma cell lines in vitro and in vivo, thereby providing a proof of concept for miRNA-based therapies for neuroblastoma. Furthermore, the combined inhibition of the direct identified targets such as CCND1, CHAF1A, INCENP and BCL-XL could reveal new vulnerabilities of high-risk neuroblastoma.